Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: An experimental study using 3-bromopyruvate on nude mice

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1443-1448

  Zhang, Xiaodong ^a,e   Varin, Emilie ^a   Briand, Mélanie ^a   Allouche, Stéphane ^b   Heutte, Natacha ^a   Schwartz, Laurent ^d   Poulain, Laurent ^a   Icard, Philippe ^a,c,f  

^a François Baclesse Anticancer Research Institute   (France)

^b Biochemistry Laboratory   (France)

^c University Hospital Center Caen   (France)

^d ECOLE POLYTECHNIQUE   (France)

^e GUANGXI MEDICAL UNIVERSITY   (China)

^f CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Energetic metabolism; Glycolysis; Mesothelioma; Nude mice

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MOUSE; FEMALE; GLYCOLYSIS; MONOTHERAPY; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

ANIMALS; CISPLATIN; ENERGY METABOLISM; ENZYME INHIBITORS; FEMALE; HUMANS; MESOTHELIOMA; MICE; MICE, NUDE; MITOCHONDRIA; OXYGEN CONSUMPTION; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES; TUMOR CELLS, CULTURED;

EID: 64949118623     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lund LG and Aust AE: Iron-catalyzed reactions may be responsible for the biochemical and biological effects of asbestos. Biofactors 3: 83-89, 1991.
2. Ribak J and Selikoff IJ: Survival of asbestos insulation workers with mesothelioma. Br J Ind Med 49: 732-735, 1992.
3. Peto J, Decarli A, La VC, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999.
4. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
5. Ko YH, Pedersen PL, and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173: 83-91, 2001.
6. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J and Pedersen PL: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324: 269-275, 2004.
7. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ and Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621,2005.
8. Leist M, Single B, Castoldi AF, Kuhnle S and Nicotera P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-1486, 1997.
9. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L and Icard P: Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26: 3561-3566, 2006.
10. Geschwind JF, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62: 3909-3913, 2002.
11. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP and Korsmeyer SJ: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003.
12. Ferreira CG, Epping M, Kruyt FA and Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res 8: 2024-2034, 2002.
13. Lieberthal W, Menza SA and Levine JS: Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 274: F315-F327, 1998.
14. Prewitt TW, Lubensky IA, Pogrebniak HW and Pass HI: Orthotopic implantation of mesothelioma in the pneumo-nectomized immune deficient rat: a model for innovative therapies. Int J Cancer 55: 877-880, 1993.
15. Astoul P and Boutin C: An experimental model of pleural cancer. Value of orthotopic implantation of human tumor tissue in nude mice. Rev Mai Respir 14: 355-362, 1997.
16. Martarelli D, Catalano A, Procopio A, Orecchia S, Libener R and Santoni G: Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 6: 130, 2006.
17. Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, and Baldi A: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 12: 6133-6143, 2006.
18. Tomasetti M, Gellert N, Procopio A and Neuzil J: A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int J Cancer 109: 641-642, 2004.
19. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A and Kroemer G: Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008.
20. Jones NA, Turner J, Mcllwrath AJ, Brown R and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819-826, 1998.